Literature DB >> 21059437

Relation of serum osteocalcin level to risk of coronary heart disease in Chinese adults.

Yifei Zhang1, Lu Qi, Weiqiong Gu, Qun Yan, Meng Dai, Juan Shi, Ying Zhai, Ying Chen, Jianmin Liu, Weiqing Wang, Guang Ning, Jie Hong.   

Abstract

Osteocalcin, a bone-derived polypeptide, was recently found to have hormonal function associated with metabolic disorders and atherosclerosis. Few studies have examined the association between circulating osteocalcin and coronary heart disease (CHD) risk. The aim of the present study was to investigate whether serum osteocalcin concentration was associated with CHD risk and metabolic profiles in Chinese adults. A total of 461 subjects (243 with CHD and 218 without CHD) who underwent coronary angiography were included. Serum osteocalcin, glucose, lipid profiles, and other biochemical markers were measured. Severity of coronary atherosclerosis was estimated by number of diseased vessels. Results showed that serum osteocalcin levels were significantly lower in the CHD group (12.2 ng/ml, 9.5 to 15.1) than in the non-CHD group (13.6 ng/ml, 10.7 to 18.0, p = 0.001) and were significantly decreased with the increasing of number of diseased vessels (p = 0.005). Serum osteocalcin concentration was inversely correlated with fasting and post load 2 hour plasma glucose and hemoglobin A(1c) (p = 0.044, 0.043, and 0.011, respectively), adjusting for CHD status. Odds ratios (95% confidence intervals) of CHD across increasing quartiles of serum osteocalcin were 0.68 (0.42 to 1.12), 0.59 (0.36 to 0.98), and 0.40 (0.23 to 0.69). The test for trend was significant (p = 0.0007). Adjusting for age, body mass index, and other conventional risk factors for CHD did not appreciably change the results. Spline regression analyses indicated a linear relation between serum osteocalcin level and CHD risk. In conclusion, our data indicate that serum osteocalcin level was associated with decreased risk of CHD and protective metabolic changes in Chinese adults.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21059437     DOI: 10.1016/j.amjcard.2010.07.013

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  14 in total

Review 1.  Association between serum osteocalcin and body mass index: a systematic review and meta-analysis.

Authors:  Hamed Kord-Varkaneh; Kurosh Djafarian; Masoud Khorshidi; Sakineh Shab-Bidar
Journal:  Endocrine       Date:  2017-08-18       Impact factor: 3.633

2.  Association between cardiovascular diseases and osteoporosis-reappraisal.

Authors:  Pawel Szulc
Journal:  Bonekey Rep       Date:  2012-08-08

3.  Association between osteocalcin and glucose metabolism: a meta-analysis.

Authors:  D-M Liu; X-Z Guo; H-J Tong; B Tao; L-H Sun; H-Y Zhao; G Ning; J-M Liu
Journal:  Osteoporos Int       Date:  2015-06-19       Impact factor: 4.507

4.  Association of bone metabolism markers with coronary atherosclerosis and coronary artery disease in postmenopausal women.

Authors:  Yan Ling; Zhen Wang; Bingjie Wu; Xin Gao
Journal:  J Bone Miner Metab       Date:  2017-06-22       Impact factor: 2.626

5.  Osteoprotegerin is a Better Serum Biomarker of Coronary Artery Calcification than Osteocalcin in Type 2 Diabetes.

Authors:  Raelene E Maser; M James Lenhard; Michael B Sneider; Ryan T Pohlig
Journal:  Endocr Pract       Date:  2015-01       Impact factor: 3.443

6.  Serum osteocalcin levels are inversely associated with abdominal aortic calcification in men with type 2 diabetes mellitus.

Authors:  N Ogawa-Furuya; T Yamaguchi; M Yamamoto; I Kanazawa; T Sugimoto
Journal:  Osteoporos Int       Date:  2013-04-06       Impact factor: 4.507

7.  Relationship between serum osteocalcin level and carotid intima-media thickness in a metabolically healthy Chinese population.

Authors:  Yuqi Luo; Xiaojing Ma; Yaping Hao; Qin Xiong; Yiting Xu; Xiaoping Pan; Yuqian Bao; Weiping Jia
Journal:  Cardiovasc Diabetol       Date:  2015-06-16       Impact factor: 9.951

8.  Osteocalcin, Vascular Calcification, and Atherosclerosis: A Systematic Review and Meta-analysis.

Authors:  Sophie A Millar; Hinal Patel; Susan I Anderson; Timothy J England; Saoirse E O'Sullivan
Journal:  Front Endocrinol (Lausanne)       Date:  2017-07-31       Impact factor: 5.555

9.  Undercarboxylated osteocalcin as a biomarker of subclinical atherosclerosis in non-dialysis patients with chronic kidney disease.

Authors:  Minfang Zhang; Zhaohui Ni; Wenyan Zhou; Jiaqi Qian
Journal:  J Biomed Sci       Date:  2015-09-17       Impact factor: 8.410

10.  Association of Serum Osteocalcin with Insulin Resistance and Coronary Atherosclerosis.

Authors:  Jee-Hyun Kang
Journal:  J Bone Metab       Date:  2016-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.